For the treatment of upper and lower respiratory tract infection, urinary tract infection, skin & skin structure infection and gynecological infection.
Faropenem is bactericidal, with a strong affinity for the high molecular penicillin-binding proteins (PBPs) of the cell wall, which is essential for the multiplication of bacilli; thus, acts by inhibiting the cell wall synthesis. Faropenem shows broad antibacterial activity against both aerobic and anaerobic Gram-positive and Gram-negative bacteria.
One tablet thrice daily orally.
Faropenem is contraindicated in patients with known hypersensitivity to any of the components of this product or to other drugs in the same class, or in patients who have demonstrated anaphylactic reactions to beta-lactams.
Patients with a history of hypersensitivity to penicillin or cephalosporins, there is a risk of occurrence of anaphylactic shock; a thorough medical history should be taken.Patients with a family history of atopy.Patients with renal insufficiency.
In pregnant women or expectant mothers, the medicine should be given only if the benefits of the treatment are greater than the risks involved.Faropenem is excreted in human milk. Therefore, faropenem should be given to nursing mothers only if the benefits outweigh the risks.Safety and efficacy in pediatric patients has not been established.
Sodium valproate: It has been reported that due to joint usage with carbapenem drugs (meropenem, panipenem and imipenem-cilastatin sodium), the concentration of valproic acid in the blood reduces, and there is a recurrence of epileptic fits.
The most frequently reported adverse reactions are diarrhea, abdominal pain, nausea and rash.